Atherosclerosis is a chronic condition where plaque gradually builds up inside the arteries, causing them to harden and narrow over time. This can lead to serious complications, including heart attack and stroke, particularly in older adults or those with existing cardiovascular risk factors.
One of the
key genetic drivers of atherosclerosis is elevated Lipoprotein(a), commonly known as Lp(a). This cholesterol-like particle contributes to plaque formation and, unlike other cardiovascular risk factors, cannot be reduced through diet, exercise, or standard cholesterol medications. Many people are unaware they have high Lp(a) levels, making targeted research into new treatments especially important.
This clinical trial is evaluating an investigational treatment designed to support heart and artery health in eligible adults at cardiovascular risk.
